StocksFundsScreenerSectorsWatchlists
CYTK

CYTK - Cytokinetics Inc Stock Price, Fair Value and News

71.68USD+0.27 (+0.38%)Delayed as of 28 Mar 2024, 12:02 pm ET

Market Summary

CYTK
USD71.68+0.27
Delayedas of 28 Mar 2024, 12:02 pm
0.38%

CYTK Alerts

  • 1 major insider sales recently.

CYTK Stock Price

View Fullscreen

CYTK RSI Chart

CYTK Valuation

Market Cap

7.4B

Price/Earnings (Trailing)

-13.98

Price/Sales (Trailing)

976.83

EV/EBITDA

184.65

Price/Free Cashflow

-17.69

CYTK Price/Sales (Trailing)

CYTK Profitability

EBT Margin

40.39%

Return on Equity

136.22%

Return on Assets

-63.84%

Free Cashflow Yield

-5.65%

CYTK Fundamentals

CYTK Revenue

Revenue (TTM)

7.5M

Rev. Growth (Yr)

-14.56%

Rev. Growth (Qtr)

342.33%

CYTK Earnings

Earnings (TTM)

-526.3M

Earnings Growth (Yr)

0.33%

Earnings Growth (Qtr)

-5.79%

Breaking Down CYTK Revenue

52 Week Range

26.5571.71
(Low)(High)

Last 7 days

3.4%

Last 30 days

-12.3%

Last 90 days

51.2%

Trailing 12 Months

83.1%

How does CYTK drawdown profile look like?

CYTK Financial Health

Current Ratio

6.12

Debt/Equity

-0.15

Debt/Cashflow

-7.1

CYTK Investor Care

Shares Dilution (1Y)

8.24%

Diluted EPS (TTM)

-5.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202398.1M10.0M7.8M7.5M
202276.5M82.5M88.5M94.6M
202158.6M57.8M21.6M70.4M
202022.2M18.7M54.3M55.8M
201934.7M35.6M31.0M26.9M
201817.9M22.4M27.0M31.5M
2017102.1M99.4M46.5M13.4M
201632.7M31.9M83.0M106.4M
201543.4M42.1M40.7M28.7M
201437.8M44.6M49.5M46.9M
20136.6M5.7M8.5M30.6M
20125.1M5.8M6.1M7.6M
20112.9M3.3M4.3M4.0M
2010055.2M28.9M2.6M
200900081.5M

Tracking the Latest Insider Buys and Sells of Cytokinetics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 14, 2024
callos andrew
acquired
-
-
16,941
evp, chief commercial officer
Mar 14, 2024
blum robert i
acquired
-
-
61,490
president & ceo
Mar 14, 2024
malik fady ibraham
acquired
-
-
42,666
evp research & development
Mar 14, 2024
wong robert
acquired
-
-
4,079
vp, chief accounting officer
Mar 06, 2024
malik fady ibraham
sold (taxes)
-542,330
66.88
-8,109
evp research & development
Mar 06, 2024
blum robert i
sold (taxes)
-1,118,570
66.88
-16,725
president & ceo
Mar 06, 2024
callos andrew
sold (taxes)
-341,289
66.88
-5,103
evp, chief commercial officer
Mar 06, 2024
wong robert
sold (taxes)
-57,316
66.88
-857
vp, chief accounting officer
Mar 05, 2024
malik fady ibraham
acquired
190,789
6.67
28,604
evp research & development
Mar 05, 2024
malik fady ibraham
sold
-2,202,610
67.5563
-32,604
evp research & development

1–10 of 50

Which funds bought or sold CYTK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-7.01
355,199
572,408
-%
Mar 11, 2024
VANGUARD GROUP INC
added
2.55
603,302,000
919,800,000
0.02%
Mar 05, 2024
Fisher Asset Management, LLC
new
-
44,754,500
44,754,500
0.02%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
129
115,262,000
136,163,000
0.01%
Mar 01, 2024
READYSTATE ASSET MANAGEMENT LP
new
-
4,700,490
4,700,490
0.16%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.65
2,740,260
4,249,640
0.02%
Feb 26, 2024
Virtu Financial LLC
new
-
3,905,000
3,905,000
0.31%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-5.46
2,859,000
4,562,000
0.04%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
new
-
2,531,170
2,531,170
0.06%
Feb 26, 2024
Neo Ivy Capital Management
sold off
-100
-470,000
-
-%

1–10 of 35

Are Funds Buying or Selling CYTK?

Are funds buying CYTK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CYTK
No. of Funds

Unveiling Cytokinetics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
11.24%
11,016,889
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
6.66%
6,530,884
SC 13G/A
Jan 25, 2024
state street corp
6.01%
5,893,358
SC 13G/A
Jan 22, 2024
blackrock inc.
16.4%
16,102,070
SC 13G/A
Feb 10, 2023
blackrock inc.
16.7%
15,767,874
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
10.64%
10,073,094
SC 13G/A
Feb 06, 2023
wellington management group llp
6.91%
6,542,724
SC 13G
Feb 03, 2023
state street corp
5.33%
5,044,914
SC 13G/A

Recent SEC filings of Cytokinetics Inc

View All Filings
Date Filed Form Type Document
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 05, 2024
144
Notice of Insider Sale Intent
Mar 05, 2024
4
Insider Trading

Peers (Alternatives to Cytokinetics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Cytokinetics Inc News

Latest updates
Defense World • 8 hours ago
Investor's Business Daily • 09 Feb 2024 • 08:00 am
Genetic Engineering & Biotechnology News • 2 months ago

Cytokinetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue342.3%2.000.001.005.002.003.0089.0072.0056.005.003.007.007.0042.004.004.005.006.007.008.009.00
Operating Expenses5.3%12912312312912911110079.0077.0075.0058.0047.0043.0037.0036.0034.0029.0030.0034.0033.0031.00
  S&GA Expenses10.0%44.0040.0040.0050.0054.0048.0043.0033.0034.0026.0021.0016.0014.0012.0014.0012.0011.0010.0010.009.007.00
  R&D Expenses3.0%85.0083.0083.0079.0075.0063.0057.0046.0043.0048.0036.0032.0029.0024.0022.0022.0018.0020.0024.0024.0024.00
EBITDA Margin16.7%5.74*4.92*3.79*0.34*0.30*0.28*0.25*0.28*0.31*0.99*0.37*----------
Interest Expenses0.4%7.007.007.007.007.007.003.003.004.004.004.004.004.004.004.004.003.001.001.001.001.00
EBT Margin3.8%0.40*0.39*0.31*0.03*0.03*0.03*0.04*0.04*0.04*0.14*0.05*----------
Net Income-5.8%-136-129-128-131-137-142-19.82-89.44-30.57-76.09-61.55-47.10-43.93-3.17-40.78-39.40-30.64-29.57-32.11-29.37-26.47
Net Income Margin-3.7%-69.89*-67.40*-54.22*-4.39*-4.11*-3.19*-2.62*-3.37*-3.06*-10.61*-2.69*-2.31*---------
Free Cashflow23.1%-74.11-96.42-122-122-101-90.37-91.33-27.75-62.49-54.47-38.29-36.15---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets11.3%8247417808901,0151,076772856841828564577534474232257290187198199211
  Current Assets11.9%628561587681795884602624536495364433474418219226234177185186208
    Cash Equivalents13.4%11310069.0010266.0010694.0011511391.0037.0045.0083.0020161.0050.0036.0040.0034.0039.0042.00
  Net PPE-9.1%69.0076.0077.0079.0080.0080.0079.0076.0073.0054.0037.0023.0013.008.006.005.005.004.003.003.003.00
Liabilities2.6%1,2111,1791,1131,1191,1231,092660740597579548509420325311302301207203195185
  Current Liabilities32.1%10378.0066.0075.0085.0076.0067.0067.0072.0081.0062.0036.0031.0028.0023.0021.0026.0022.0022.0026.0022.00
  Long Term Debt-4.1%58.0061.0062.0064.0064.0064.0062.0061.0047.0030.0036.0041.0046.0046.0046.0045.0045.0045.0044.0036.0040.00
    LT Debt, Current-10.00---1.00----17.0011.006.00-------6.003.00
    LT Debt, Non Current-4.1%58.0061.0062.0064.0064.0064.0062.0061.0047.0030.0036.0041.0046.0046.0046.0045.0045.0045.0044.0036.0040.00
Shareholder's Equity-Infinity%-386----107-11111624424916.0068.00113150-----3.0026.00
  Retained Earnings-5.6%-2,112-2,000-1,800-1,700-1,585-1,448-1,306-1,286-1,207-1,177-1,101-1,039-992-948-945-904-865-834-804-772-743
  Additional Paid-In Capital12.3%1,7261,5371,5141,4901,4821,4381,4221,4061,4521,4261,1171,1071,1051,097866857853814799775769
Shares Outstanding-102---95.00---85.00---71.00---59.00----
Float---2,000---2,000---1,443---1,413---653--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations23.0%-74.03-96.20-121-122-98.19-84.04-90.47-26.81-44.74-38.77-29.50-29.5252.0014.00-27.44-30.13-19.05-20.27-24.68-26.91-12.33
  Share Based Compensation4.1%19.0019.0019.0015.0013.0013.0012.009.007.008.007.005.005.005.005.004.003.003.003.002.00-
Cashflow From Investing-211.5%-81.4173.0082.0016529.00-29265.00-64.2847.00-20819.00-5.28-173-10135.0043.00-10514.00-2.7720.0027.00
Cashflow From Financing211.3%16954.005.00-7.1830.003893.0094.0020.003013.00-3.604.002264.00-0.0112112.0022.004.000.00

CYTK Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Total revenues$ 7,530$ 94,588$ 70,428
Operating expenses:   
Research and development330,123240,813159,938
General and administrative173,612177,97796,803
Total operating expenses503,735418,790256,741
Operating loss(496,205)(324,202)(186,313)
Interest expense(28,306)(19,414)(16,440)
Loss on extinguishment of debt0(24,939)0
Non-cash interest expense on liabilities related to revenue participation right purchase agreements(29,362)(31,742)(12,892)
Interest and other income, net27,62911,342331
Net loss$ (526,244)$ (388,955)$ (215,314)
Net loss per share - basic$ (5.45)$ (4.33)$ (2.8)
Net loss per share - diluted$ (5.45)$ (4.33)$ (2.8)
Weighted-average number of shares used in computing net loss per share - basic96,52489,82576,886
Weighted-average number of shares used in computing net loss per share - diluted96,52489,82576,886
Other comprehensive gain (loss):   
Unrealized gain (loss) on available-for-sale securities, net$ 3,600$ (2,721)$ (1,018)
Foreign currency translation adjustments(20)00
Comprehensive loss(522,664)(391,676)(216,332)
Research and Development Revenues [Member]   
Revenues:   
Total revenues4,0306,58810,572
License Revenues [Member]   
Revenues:   
Total revenues0054,856
Milestone Revenues [Member]   
Revenues:   
Total revenues3,5001,0005,000
Realization of Revenue Participation Right Purchase Agreement [Member]   
Revenues:   
Total revenues$ 0$ 87,000$ 0

CYTK Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 113,024$ 65,582
Short-term investments501,800716,995
Accounts receivable1,283147
Prepaid expenses and other current assets11,94412,462
Total current assets628,051795,186
Long-term investments40,53446,708
Property and equipment, net68,74880,453
Operating lease right-of-use assets78,98782,737
Other assets7,9969,691
Total assets824,3161,014,775
Current liabilities:  
Accounts payable21,50725,611
Accrued liabilities42,64144,096
Short-term operating lease liabilities17,89112,829
Current portion of long-term debt10,080958
Other current liabilities10,5591,123
Total current liabilities102,67884,617
Term loan, net58,38463,810
Convertible notes, net548,989545,808
Liabilities related to revenue participation right purchase agreements, net379,975300,501
Long-term operating lease liabilities120,427126,895
Other non-current liabilities1861,044
Total liabilities1,210,6391,122,675
Commitments and contingencies
Stockholders' deficit:  
Preferred stock, $0.001 par value: Authorized: 10,000,000 shares; Issued and outstanding: none00
Common stock, $0.001 par value: Authorized: 163,000,000 shares; Issued and outstanding: 101,637,922 shares at December 31, 2023 and 94,833,975 shares at December 31, 202210294
Additional paid-in capital1,725,8231,481,590
Accumulated other comprehensive loss(10)(3,590)
Accumulated deficit(2,112,238)(1,585,994)
Total stockholders' deficit(386,323)(107,900)
Total liabilities and stockholders' deficit$ 824,316$ 1,014,775
CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.cytokinetics.com
 EMPLOYEES409

Cytokinetics Inc Frequently Asked Questions


What is the ticker symbol for Cytokinetics Inc? What does CYTK stand for in stocks?

CYTK is the stock ticker symbol of Cytokinetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cytokinetics Inc (CYTK)?

As of Wed Mar 27 2024, market cap of Cytokinetics Inc is 7.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYTK stock?

You can check CYTK's fair value in chart for subscribers.

What is the fair value of CYTK stock?

You can check CYTK's fair value in chart for subscribers. The fair value of Cytokinetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cytokinetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CYTK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cytokinetics Inc a good stock to buy?

The fair value guage provides a quick view whether CYTK is over valued or under valued. Whether Cytokinetics Inc is cheap or expensive depends on the assumptions which impact Cytokinetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYTK.

What is Cytokinetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, CYTK's PE ratio (Price to Earnings) is -13.98 and Price to Sales (PS) ratio is 976.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYTK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cytokinetics Inc's stock?

In the past 10 years, Cytokinetics Inc has provided 0.217 (multiply by 100 for percentage) rate of return.